Fibroblast growth factor 19 level in blood plasma, thyroid tumors and metastasis
Authors:
- N.YA. KobrynskaNKN.YA. Kobrynska
- V.M. PushkarevVPV.M. Pushkarev
- N.I. LevchukNLN.I. Levchuk
- O.I. KovzunOKO.I. Kovzun
- I.I. KomisarenkoIKI.I. Komisarenko
- B.B. GudaBGB.B. Guda
- TronkoTRTronko
Open Access
- 27 March 2026
- journal article
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 135-139
Abstract
Background. The endocrine subfamily of fibroblast growth factor 19 (FGF19) consists of FGF19, FGF21, and FGF23. Numerous data indicate that FGF19 is involved in carcinogenesis, epithelial-mesenchymal transition, metastasis formation, and tumor resistance to inhibitors. The purpose of the study was to compare the levels of FGF19 in tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma (PTC), metastasis (Mts), and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the IEM clinic, were used for research. The amount of FGF19 was determined using enzyme immunoassay kits. Results. The level of FGF19 in the tissue of follicular adenoma and goiter exceeded the levels in conditionally normal tissue. There was also significant difference between normal tissue and РТС tissues with and without Mts. It is important to note that the level of FGF19 in metastasis was higher than in the tumor tissue of the РТС. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 significantly exceeded its level in control plasma and in the blood of patients with PTC without Mts. In plasma of patients with PTC without Mts, the concentration of the FGF19 did not differ from its concentration in blood of healthy people. Conclusions. Our data indicate significant differences in the concentration of FGF19 between tumor tissues of PTC and Mts. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 exceeded its level in control plasma and the concentration of FGF19 in the blood of patients with PTC without Mts. There was no difference between level of FGF19 in the blood of patients with PTC without Mts and in control plasma. The latter facts may be useful for predicting the formation of Mts.Keywords
This publication has 22 references indexed in Scilit:
- Enhanced expression of FGF19 predicts poor prognosis in patients with non-small cell lung cancerJournal of Thoracic Disease, 2021
- FGF/FGFR signaling in health and diseaseSignal Transduction and Targeted Therapy, 2020
- Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104Oncogene, 2020
- Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancerCytokine, 2018
- FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4–GSK3β–Nrf2 SignalingCancer Research, 2017
- FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenibJournal of Experimental & Clinical Cancer Research, 2017
- FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activationOncotarget, 2015
- Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid CancerOtolaryngology–Head and Neck Surgery, 2015
- Interaction of tumor cells with the microenvironmentCell Communication and Signaling, 2011
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976